Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS safety_alert · 2011-04-18

Clinical Trial Update: Fracture Risk With Thiazolidinediones

View source ↗

Summary

A clinical trial update examines fracture risk associated with thiazolidinedione therapy in type 2 diabetes, noting potential increased fracture risk with these…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rosiglitazone (rosiglitazone)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Fractures, Bone, Type II Diabetes | Status: COMPLETED | Results posted: 2011-04-18